TapewireFind a company

person · Reporting owner

Vitale Philip J

Disclosed activity across 1 company

Tapewire entity
125106
SEC CIK
0001597792

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Perspective Therapeutics, Inc.ISR · Entity 694DirectorJuly 21, 2022July 28, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Perspective Therapeutics, Inc.

Report date July 21, 2022 · Filed July 28, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2032-07-21Direct425,000 Reported balance After 2022-07-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2022-07-21 · Grant · Acquired 135,000 · Balance 425,000

F1: One-third vested on 7/21/2022, and the remaining two-thirds will vest over the next two (2) years, commencing on 7/21/2023, until fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: One-third vested on 7/21/2022, and the remaining two-thirds will vest over the next two (2) years, commencing on 7/21/2023, until fully vested.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 21, 2022 Filed Jul 28, 2022 21:19 UTC Perspective Therapeutics, Inc. ISR · Entity 694 GrantStock Options (right to buy) · Derivative 135,000 $0.00 Strike: $0.33 $0.00
Disclosure

SEC source: 0001437749-22-018029 · rdgdoc.xml · derivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 425,000

Underlying: Common Stock · 135,000 shares

Expires 2032-07-21

F1 · derivative.exercise_date: One-third vested on 7/21/2022, and the remaining two-thirds will vest over the next two (2) years, commencing on 7/21/2023, until fully vested.

Read SEC document
July 01, 2021 Filed Jul 6, 2021 20:18 UTC Perspective Therapeutics, Inc. ISR · Entity 694 GrantStock Options (right to buy) · Derivative 135,000 $0.00 Strike: $0.79 $0.00
Disclosure

SEC source: 0001437749-21-016439 · rdgdoc.xml · derivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Philip James Vitale Rev Living Trust Dtd 11/6/07

Disclosed balance after: 290,000

Underlying: Common Stock · 135,000 shares

Expires 2031-07-01

F1 · derivative.exercise_date: One-third vested on 7/1/2021, and the remaining two-thirds will vest over the next two (2) years, commencing on 7/1/2022, until fully vested.

F1 · derivative.expiration_date: One-third vested on 7/1/2021, and the remaining two-thirds will vest over the next two (2) years, commencing on 7/1/2022, until fully vested.

Read SEC document
October 22, 2020 Filed Oct 28, 2020 20:37 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseWarrant (right to buy) · Derivative 10,000 $0.00 Strike: $0.57 $0.00
Disclosure

SEC source: 0001437749-20-021849 · rdgdoc.xml · derivative · entry 2

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Philip James Vitale Rev Living Trust Dtd 11/6/07

Disclosed balance after: 155,000

Underlying: Common Stock · 10,000 shares

Expires 2025-10-22

F2 · shares: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025.

F2 · derivative.exercise_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025.

F2 · derivative.expiration_date: Purchased pursuant to public offering that closed on October 22, 2020. Each share of common stock purchased included one-half of a warrant. Each whole warrant is exercisable to purchase one share of common stock at an exercise price of $0.57 per share. Each warrant is immediately exercisable, and will expire October 22, 2025.

Read SEC document
October 22, 2020 Filed Oct 28, 2020 20:37 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 20,000 $0.52 $10,400.00
Disclosure

SEC source: 0001437749-20-021849 · rdgdoc.xml · nonDerivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Philip James Vitale Rev Living Trust Dtd 11/6/07

Disclosed balance after: 130,000

F1 · shares: Purchased pursuant to public offering that closed on October 22, 2020.

F1 · price: Purchased pursuant to public offering that closed on October 22, 2020.

Read SEC document
June 23, 2020 Filed Jul 15, 2020 21:08 UTC Perspective Therapeutics, Inc. ISR · Entity 694 GrantStock Options (right to buy) · Derivative 30,000 $0.00 Strike: $0.61 $0.00
Disclosure

SEC source: 0001437749-20-015197 · rdgdoc.xml · derivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,000

Underlying: Common Stock · 30,000 shares

Expires 2030-06-23

F1 · derivative.exercise_date: 25% vested as of 6/23/2020, and the remaining 75% will vest over the next three (3) years, commencing on 6/23/2021, until fully vested.

Read SEC document
June 18, 2019 Filed Jun 24, 2019 20:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 GrantStock Options (right to buy) · Derivative 30,000 $0.00 Strike: $0.43 $0.00
Disclosure

SEC source: 0001437749-19-012548 · rdgdoc.xml · derivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 30,000 shares

Expires 2029-06-18

F1 · derivative.exercise_date: 25% vested as of 6/18/2019, and the remaining 75% will vest over the next three (3) years, commencing on 6/18/2020, until fully vested.

Read SEC document
November 13, 2018 Filed Nov 15, 2018 22:45 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 30,000 $0.43 $12,900.00
Disclosure

SEC source: 0001437749-18-020965 · rdgdoc.xml · nonDerivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Read SEC document
July 18, 2018 Filed Jul 27, 2018 01:28 UTC Perspective Therapeutics, Inc. ISR · Entity 694 GrantStock Options (right to buy) · Derivative 25,000 $0.00 Strike: $0.55 $0.00
Disclosure

SEC source: 0001437749-18-013828 · rdgdoc.xml · derivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 25,000 shares

Expires 2028-07-18

F1 · derivative.exercise_date: 25% vested as of 7/18/2018, and the remaining 75% will vest over the next three (3) years, commencing on 7/18/2019, until fully vested.

Read SEC document
June 26, 2018 Filed Jul 2, 2018 21:21 UTC Perspective Therapeutics, Inc. ISR · Entity 694 GrantStock Options (right to buy) · Derivative 5,000 $0.00 Strike: $0.45 $0.00
Disclosure

SEC source: 0001437749-18-012804 · rdgdoc.xml · derivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 5,000 shares

Expires 2028-06-26

F1 · derivative.exercise_date: 25% vested as of 6/26/2018, and the remaining 75% will vest over the next three (3) years, commencing on 6/26/2019, until fully vested.

Read SEC document
March 14, 2018 Filed Mar 15, 2018 22:05 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 10,000 $0.44 $4,399.00
Disclosure

SEC source: 0001437749-18-004772 · rdgdoc.xml · nonDerivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 100 $0.44 $44.40
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 15

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 600 $0.45 $269.40
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 14

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,900

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 12,851 $0.45 $5,782.95
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 13

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,300

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 300 $0.44 $132.75
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 12

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,449

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 300 $0.44 $130.86
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 11

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,149

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 496 $0.44 $218.19
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 10

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,849

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 1,606 $0.44 $706.64
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 9

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,353

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 1,400 $0.44 $614.60
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 8

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,747

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 18 $0.44 $7.83
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 7

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,347

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 3,049 $0.44 $1,335.46
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 6

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,329

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 400 $0.44 $175.56
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 5

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,280

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 200 $0.43 $86.08
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 4

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,880

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 8,480 $0.43 $3,646.40
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 3

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,680

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 100 $0.43 $42.51
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 2

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,200

Read SEC document
November 16, 2017 Filed Nov 17, 2017 21:51 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 100 $0.43 $42.50
Disclosure

SEC source: 0001642247-17-000020 · primary_doc.xml · nonDerivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,100

Read SEC document
June 27, 2017 Filed Jun 29, 2017 21:30 UTC Perspective Therapeutics, Inc. ISR · Entity 694 GrantStock Options (right to buy) · Derivative 5,000 $0.00 Strike: $0.61 $0.00
Disclosure

SEC source: 0001642247-17-000014 · primary_doc.xml · derivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2027-06-27

F1 · derivative.exercise_date: 25% vested as of 6/27/2017, and the remaining 75% will vest over the next three (3) years, commencing on 6/27/2018, until fully vested.

Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:38 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 2,700 $0.66 $1,768.50
Disclosure

SEC source: 0001642247-17-000001 · primary_doc.xml · nonDerivative · entry 3

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:38 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 100 $0.66 $65.75
Disclosure

SEC source: 0001642247-17-000001 · primary_doc.xml · nonDerivative · entry 2

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,300

Read SEC document
January 04, 2017 Filed Jan 6, 2017 22:38 UTC Perspective Therapeutics, Inc. ISR · Entity 694 PurchaseCommon Stock 17,200 $0.66 $11,352.00
Disclosure

SEC source: 0001642247-17-000001 · primary_doc.xml · nonDerivative · entry 1

Vitale Philip J · CIK 0001597792 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,200

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.